CONRAY 400 66.8 %
IOTHALAMATE SODIUM : 66.8 % · DIN 00131547 · TYCO HEALTHCARE
Health Canada status: CANCELLED POST MARKET
What is CONRAY 400?
CONRAY 400 66.8 % contains IOTHALAMATE SODIUM : 66.8 %. It is listed in the Health Canada Drug Product Database under DIN 00131547, held by TYCO HEALTHCARE, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 12-Jan-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00131547 |
|---|---|
| Brand name | CONRAY 400 |
| Generic / active ingredient | IOTHALAMATE SODIUM : 66.8 % |
| Manufacturer | TYCO HEALTHCARE |
| Strength | 66.8 % |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | V08AA04 IOTALAMIC ACID |
| AHFS class | 36:68.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 12-Jan-2010 |
| Original market date | 1986-12-18 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code V08AA04 IOTALAMIC ACID. 0 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CONRAY 30 | 300 MG | SOLUTION | LIEBEL-FLARSHEIM CANADA INC | CANCELLED POST MARKET | DIN 00223107 |
| CONRAY 325 | 54.3 % | SOLUTION | TYCO HEALTHCARE | CANCELLED POST MARKET | DIN 00405302 |
| CONRAY 43 | 430 MG | SOLUTION | LIEBEL-FLARSHEIM CANADA INC | CANCELLED POST MARKET | DIN 00477095 |
| CONRAY 60 | 600 MG | SOLUTION | LIEBEL-FLARSHEIM COMPANY LLC | CANCELLED POST MARKET | DIN 00131237 |
| CYSTO CONRAY INJ 43% | 430 MG | LIQUID | MALLINCKRODT CANADA INC. | CANCELLED POST MARKET | DIN 00274194 |
| CYSTO-CONRAY II | 172 MG | SOLUTION | LIEBEL-FLARSHEIM COMPANY LLC | CANCELLED POST MARKET | DIN 00397466 |
| VASCORAY | 260 MG | SOLUTION | TYCO HEALTHCARE | CANCELLED POST MARKET | DIN 00131628 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.